Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer

Evanthia T. Roussos Torres • 14 Sep 2021
ESMO 2021
Breast Cancer General Entinostat Ipilimumab Nivolumab

Evanthia T. Roussos Torres, MD, PhD, Keck School of Medicine of USC, Los Angeles, CA, discusses the results of a study evaluating the combination of entinostat, nivolumab and ipilimumab in patients with advanced HER2-negative breast cancer. At the recomended Phase II dose, this combinatorial approach was associated with expected immune-related adverse events in advanced HER2-negative breast cancer. An overall response rate of 30% suggests this combination should be evaluated further. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

More from Evanthia T. Roussos Torres

Preclinical research into the effects of entinostat on immune response
1:40
Preclinical research into the effects of entinostat on immune response
Evanthia T. Roussos Torres • 14 Sep 2021
Combining epigenetic modulators and immune checkpoint blockade in cancer
3:23
Combining epigenetic modulators and immune checkpoint blockade in cancer
Evanthia T. Roussos Torres • 14 Sep 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals